which glp 1 approved for weight loss Comparing Ozempic, Wegovy and Other GLP-1 Drugs How Employers Can Optimize Benefits

Amongst, overweight and obese patients defined by BMI in 2024 (58.9% [95% CIs 53.3-64.2%] female [182/309], median [IQR] age 56.6 [46.2-66.1]) GLP 1RA use has increased from 3.2% (10/309 [95% CIs 1.8-5.9%]) to 13.6% (42/309 [95% CIs 10.2-17.9%] [p=7.1x10-6])

GLP-1, generally sh

#Watch #GLP1 #WeightLossDrugs #PharmaNews #IndianPharma #Semaglutide #Mounjaro #Wegovy #Ozempic #PatentExpiry #HealthcareBusiness #CNBCTV18Digital

Here, the authors report cryo-EM structures of tirzepatide-bound GIPR and GLP-1R, peptide 20-bound GIPR, GLP-1R and GCGR, revealing the molecular basis of their multiplexed pharmacological actions.